Baidu
map

Pain:癌症患者中出现慢性疼痛的患病率和发病率

2017-03-10 MedSci MedSci原创

近期,发表在杂志Pain上的文章进行了一项前瞻性多中心研究,以估计在法国患有癌症的患者中具有或不具有神经病特征的慢性疼痛的患病率和发病率。此项研究招募了12个肿瘤学单位中癌症治疗进行两周内观察的所有连续门诊患者(n = 1885),共包括1805名患者。患者在访视1期间进行临床检查,并完成问卷以检测慢性疼痛(定义为每日疼痛,至少三个月)及其强度,位置和神经病特征(即DN4得分≥4)。疼痛对生活质量

近期,发表在杂志Pain上的文章进行了一项前瞻性多中心研究,以估计在法国患有癌症的患者中具有或不具有神经病特征的慢性疼痛的患病率和发病率。


此项研究招募了12个肿瘤学单位中癌症治疗进行两周内观察的所有连续门诊患者(n = 1885),共包括1805名患者。患者在访视1期间进行临床检查,并完成问卷以检测慢性疼痛(定义为每日疼痛,至少三个月)及其强度,位置和神经病特征(即DN4得分≥4)。疼痛对生活质量的影响用简明疼痛量表进行评估。访视1期间无疼痛的患者被纳入发病率研究,并进行随后3个月和6个月时的随访。

研究结果显示:慢性疼痛的总发病率为28.2%[95%CI:26.3-30.5],范围为22.5%至35.4% ,这取决于原发性肿瘤的位置。这些患者中有20.9%的患者存在神经病变特征,根据原发肿瘤的位置,患病率为2.9%至9.7%。具有神经性特征的患者的疼痛强度和干扰更高。

根据原发性肿瘤位置,6个月随访期间的慢性疼痛的发生率为13%至28%,并且在19.9%的慢性疼痛患者中发现神经病特征。


原始出处:
Bouhassira D, Luporsi E, Krakowski I. Prevalence and incidence of chronic pain with or without neuropathic characteristics in patients with cancer. Pain. 2017 Mar 4. doi: 10.1097/j.pain.0000000000000895. 

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1823311, encodeId=902a182331188, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Tue Jul 25 15:55:00 CST 2017, time=2017-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=182186, encodeId=4dcc182186f2, content=继续学习中,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Thu Mar 23 13:39:41 CST 2017, time=2017-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250453, encodeId=de7312504537c, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Sun Mar 12 03:55:00 CST 2017, time=2017-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1260030, encodeId=dc09126003015, content=<a href='/topic/show?id=fd52535e38b' target=_blank style='color:#2F92EE;'>#慢性疼痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53573, encryptionId=fd52535e38b, topicName=慢性疼痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=976a57, createdName=liubm555, createdTime=Sun Mar 12 03:55:00 CST 2017, time=2017-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289523, encodeId=56ab128952310, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Sun Mar 12 03:55:00 CST 2017, time=2017-03-12, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1823311, encodeId=902a182331188, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Tue Jul 25 15:55:00 CST 2017, time=2017-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=182186, encodeId=4dcc182186f2, content=继续学习中,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Thu Mar 23 13:39:41 CST 2017, time=2017-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250453, encodeId=de7312504537c, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Sun Mar 12 03:55:00 CST 2017, time=2017-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1260030, encodeId=dc09126003015, content=<a href='/topic/show?id=fd52535e38b' target=_blank style='color:#2F92EE;'>#慢性疼痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53573, encryptionId=fd52535e38b, topicName=慢性疼痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=976a57, createdName=liubm555, createdTime=Sun Mar 12 03:55:00 CST 2017, time=2017-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289523, encodeId=56ab128952310, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Sun Mar 12 03:55:00 CST 2017, time=2017-03-12, status=1, ipAttribution=)]
    2017-03-23 往日如昨

    继续学习中,谢谢

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1823311, encodeId=902a182331188, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Tue Jul 25 15:55:00 CST 2017, time=2017-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=182186, encodeId=4dcc182186f2, content=继续学习中,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Thu Mar 23 13:39:41 CST 2017, time=2017-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250453, encodeId=de7312504537c, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Sun Mar 12 03:55:00 CST 2017, time=2017-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1260030, encodeId=dc09126003015, content=<a href='/topic/show?id=fd52535e38b' target=_blank style='color:#2F92EE;'>#慢性疼痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53573, encryptionId=fd52535e38b, topicName=慢性疼痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=976a57, createdName=liubm555, createdTime=Sun Mar 12 03:55:00 CST 2017, time=2017-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289523, encodeId=56ab128952310, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Sun Mar 12 03:55:00 CST 2017, time=2017-03-12, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1823311, encodeId=902a182331188, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Tue Jul 25 15:55:00 CST 2017, time=2017-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=182186, encodeId=4dcc182186f2, content=继续学习中,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Thu Mar 23 13:39:41 CST 2017, time=2017-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250453, encodeId=de7312504537c, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Sun Mar 12 03:55:00 CST 2017, time=2017-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1260030, encodeId=dc09126003015, content=<a href='/topic/show?id=fd52535e38b' target=_blank style='color:#2F92EE;'>#慢性疼痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53573, encryptionId=fd52535e38b, topicName=慢性疼痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=976a57, createdName=liubm555, createdTime=Sun Mar 12 03:55:00 CST 2017, time=2017-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289523, encodeId=56ab128952310, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Sun Mar 12 03:55:00 CST 2017, time=2017-03-12, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1823311, encodeId=902a182331188, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Tue Jul 25 15:55:00 CST 2017, time=2017-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=182186, encodeId=4dcc182186f2, content=继续学习中,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Thu Mar 23 13:39:41 CST 2017, time=2017-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250453, encodeId=de7312504537c, content=<a href='/topic/show?id=7d6f52988e1' target=_blank style='color:#2F92EE;'>#患病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52988, encryptionId=7d6f52988e1, topicName=患病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Sun Mar 12 03:55:00 CST 2017, time=2017-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1260030, encodeId=dc09126003015, content=<a href='/topic/show?id=fd52535e38b' target=_blank style='color:#2F92EE;'>#慢性疼痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53573, encryptionId=fd52535e38b, topicName=慢性疼痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=976a57, createdName=liubm555, createdTime=Sun Mar 12 03:55:00 CST 2017, time=2017-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289523, encodeId=56ab128952310, content=<a href='/topic/show?id=cbb8e1356f7' target=_blank style='color:#2F92EE;'>#癌症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71356, encryptionId=cbb8e1356f7, topicName=癌症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=10ba218, createdName=zgwhgch, createdTime=Sun Mar 12 03:55:00 CST 2017, time=2017-03-12, status=1, ipAttribution=)]

相关资讯

ACS Nano:突破!科学家利用来自尿液的生物标志物进行早期癌症筛查

日前,来自韩国蔚山国家科学技术研究所的研究人员通过研究开发出了一种新技术,该技术能够有效在尿液或血液中有效鉴别出促进癌症发生的物质,相关研究刊登于国际杂志 ACS Nano 上。文章中,研究人员开发出了一种集成的离心微流体平台(Exodisc),这种设备能够对尿液中的胞外膜泡 (extracellular vesicles,EVs) 进行分离。研究人员希望这种技术或能用于临床设备中来检测尿液中基于

Science: 保持T细胞CD28/B7信号通路的激活对于针对PD-L1的靶向治疗具有重大意义

T细胞CD28/B7信号通路的激活是针对PD-L1的靶向治疗的重要组成部分

ctDNA与癌症早筛,这项新突破是否会带来颠覆?

2017年3月6日,美国加州大学圣地亚哥分校生物工程系张鹍教授和他团队在《Nature Genetics》杂志公布了高通量甲基化无创检测新技术,可以快速检测肿瘤细胞,并确定肿瘤在体内的生长位置。ctDNA液体活检用于癌症早期筛查再次获得突破。

蟾蜍的干燥皮肤分泌物可用于治疗癌症患者

来自蟾蜍的干燥皮肤分泌物可用于治疗癌症患者,并对癌症患者有很大的益处。昆士兰大学的研究人员正在与中国香港理工大学(PolyU)的同事合作,开发一种源自 Chan Su 的癌症治疗方法,Chan Su 是来自蟾蜍副产品的中药。UQ 的药学院药学澳大利亚卓越中心(PACE)的 Harendra Parekh 博士说:“Chan Su 在中国被用于治疗心力衰竭,喉咙痛,皮肤病等疾病”。Parekh 教授

CANCER RES:胶质母细胞瘤信号通路新进展

北海道大学遗传基因病研究所的一项研究表明,癌胚抗原相关的细胞粘附分子Ceacam1L通过激活c-Src / STAT3信号通路维持GIC的功能并能够导致肿瘤发生。

PLOS ONE:电子烟同样会释放大量致癌物!

波特兰州立大学的研究人员发现当电子烟高功率运行时,其气化物中会形成大量的致癌物:苯。研究报告发表于 8 日的线上杂志《国家公共图书馆》中。

Baidu
map
Baidu
map
Baidu
map